Authors : N. Naveen Kumar; Dr. Umadevi Ramamoorthy

Volume/Issue : Volume 11 - 2026, Issue 8 - August

Google Scholar : https://tinyurl.com/3yvasrce

DOI : https://doi.org/10.38124/ijisrt/26aug698

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : The financial results and long-term viability of corporate organisations are Financial leverage has a major impact. This research looks at The impact of financial leverage on the financial performance of a few Indian listed pharmaceutical businesses between 2021 and 2024. The annual reports and audited financial statements of particular pharmaceutical businesses were used to gather secondary data. While Financial performance is evaluated using Return on Assets (ROA), Return on Equity (ROE), Earnings per Share (EPS), and Return on Capital Employed (ROCE), financial leverage is quantified using metrics like the Debt-to-Equity Ratio (DER), Debt Ratio (DR), and Interest Coverage Ratio (ICR). To look into the connection between financial success and financial 111 leverage and to create predictive models, the gathered data is pre processed and analysed using Pearson Correlation Analysis, Multiple Random Forest Regression, Decision Tree Regression, Linear Regression,, and K-Means Clustering. R2 Mean Absolute 222 Error (MAE), score Mean Squared Error (MSE), and 666 333 utilize Root Mean Squared Error (RMSE) to evaluate the prediction models' performance.

Keywords : Financial Leverage, Financial Performance, Machine Learning, Multiple Random Forest, Decision Tree, and Linear 44 Regression Pearson Correlation, K-Means Clustering, Pharmaceutical Companies, India.

References :

1. G. James, D. Witten, T. Hastie, and R. Tibshirani, An Introduction to Statistical Learning with Applications in R, 2nd ed. New York, NY, USA: Springer, 2021.
2. A. Géron, Hands-On Machine Learning with Scikit-Learn, Keras, and TensorFlow, 3rd ed. Sebastopol, CA, USA: O'Reilly Media, 2022.
3. P. Tan, M. Steinbach, and A. Karpatne, Introduction to Data Mining, 3rd ed. Pearson, 2021.
4. S. Raschka, Y. Liu, and V. Mirjalili, Machine Learning with PyTorch and Scikit-Learn. Birmingham, U.K.: Packt Publishing, 2022.
5. P. Paul, “A Study of Multilayered Profitability Analysis by Using DuPont Model: Evidence from Indian Pharmaceutical Industry,” Global Business Review, vol. 26, no. 2, pp. 408–420, 2021.
6. S. Kumar and S. Bansal, “Capital Structure, Competitive Intensity and Firm Performance: An Analysis of Indian Pharmaceutical Companies,” Managerial Finance, vol. 47, no. 9, pp. 1357–1382, 2021.
7. M. Sharma and P. Sharma, “Impact of R&D Activities on the Financial Performance: Empirical Evidence from Indian Pharmaceutical Companies,” International Journal of Pharmaceutical and Healthcare Marketing, vol. 16, no. 2, pp. 182–203, 2022.
8. P. Tomar and G. Chauhan, “Capital Structure, Profitability and Sustainable Financing: Evidence from Pharmaceutical Companies,” International Journal of Research and Scientific Innovation, vol. 13, no. 5, pp. 1735–1748, 2026.
9. R. Manigandan, V. Balaji, R. Supriya, A. Shakti Priya, and N. Parthasarathi, “Intellectual Capital, Independent Directors and Leverage as Determinants of Sustainable Growth in Indian Pharmaceutical Companies Listed in the NSE NIFTY Pharma Index,” Discover Sustainability, vol. 7, Art. no. 114, 2026.
10. M. P. Fernandes and H. R. Khanapuri, “Navigating Financial Frameworks: How Macroeconomic Drivers Shape Capital Structure Strategies,” Indian Journal of Finance, vol. 20, no. 5, 2026.
11. Z. Yu, “Research on Corporate Financial Risk Assessment Model Based on Data Analysis,” Machine Intelligence and Digital Applications, 2026.
12. V. Sagar G., S. Ali, and S. P. Chakrabarty, “Machine Learning Based Stress Testing Framework for Indian Financial Market Portfolios,” arXiv preprint arXiv:2507.02011, 2025.
13. G. Singh, “Machine Learning Models in Stock Market Prediction,” arXiv preprint arXiv:2202.09359, 2022.
14. S. Issa and H. Issa, “Exploring Corporate Capital Structure and Overleveraging in the Pharmaceutical Industry,” Risks, vol. 13, no. 2, Art. no. 26, Feb. 2025. doi: 10.3390/risks13020026.
15. N. Prasad, M. K. Verma, N. Tanwar, and M. Kumar, “Capital Structure Impact on Firm Performance: An Empirical Study of the Pharmaceutical Sector,” Economic Affairs, vol. 69, no. 2, pp. 843–848, 2024. doi: 10.46852/0424-2513.3.2024.8.